tbuckley/cabot-search huggingface dataset:
P2.16-25 Lower Hiliar Lymph Node Upstaging in Early NSCLC Vats Surgery is Related to Tumor Location and Does Not Afect Survival
Authors: M. Boada, R. Guzman, M. Montesinos, A. Libreros, A. Guirao, D. Sanchez, J.M. Gimferrer, L. Molins
Journal: Journal of Thoracic Oncology (2018)
Exploring the effectiveness of crisis counselling and psycho-education in relation to improving mental wellbeing, quality of life and treatment compliance of breast cancer patients in Qatar
Authors: R. Alsulaiman, S. Bujassoum, A. Bener, L. Doodson, S. Ghuloum, A. Lemaux, H. Bugrein, R. Alasaam, A. Karim
Journal: Annals of Oncology (2018)
P1.01-75 Utility of cfDNA Testing for Acquired Resistance: The Memorial Sloan Kettering Experience with Plasma EGFR T790M Clinical Testing
Authors: M. Offin, M. Myers, S. Josyula, R. Shen, L. Borsu, D. Tsui, G. Riely, C. Rudin, H. Yu, B. Li, M. Arcila
Journal: Journal of Thoracic Oncology (2018)
P2.03-29 Prognostic Significance of Phosphorylated Fyn in Patients with Lung Adenocarcinoma
Authors: S. Nishikawa, T. Menju, T. Sowa, T. Nakanishi, K. Takahashi, R. Miyata, H. Ishikawa, M. Noguchi, Y. Yutaka, M. Hamaji, D. Nakajima, A. Ohsumi, T. Sato, T. Yoshikawa, M. Sonobe, H. Date
Journal: Journal of Thoracic Oncology (2018)
MA15.06 Circulating Tumor DNA Portrays the Resistance Landscape to a Novel Third Generation EGFR Inhibitor, AC0010
Authors: Q. Zhou, Y. Zhang, Z. Chen, C. Xu, J.-. Yang, X. Zhang, X. Bai, H. Yan, Z. Xie, W.-. Li, S. Chuai, J. Ye, H. Zhang-Han, Z. Zhang, Y. Wu
Journal: Journal of Thoracic Oncology (2018)
Updated results of GETUG-12, a phase III trial of docetaxel-based chemotherapy in high-risk localized prostate cancer, with a 12-year follow-up
Authors: K. Fizazi, A. Carmel, F. Joly, R. Delva, G. Gravis, F. Rolland, F. Priou, J.-M. Ferrero, N. Houede, L. Mourey, C. Theodore, I. Krakowski, J.-F. Berdah, M. Baciuchka Palmaro, B. Laguerre, A. Flechon, A. Ravaud, M. Brihoum, S. Culine, G. Le Teuff
Journal: Annals of Oncology (2018)
Gemcitabine plus afatinib versus gemcitabine alone in metastatic pancreatic cancer: An explorative randomized AIO phase II trial (ACCEPT)
Authors: M. Haas, D. Waldschmidt, M. Stahl, A. Reinacher-Schick, J. Freiberg-Richter, F. Kaiser, S. Kanzler, N. Frickhofen, T. Seufferlein, T. Dechow, R.J.C. Mahlberg, P. Malfertheiner, G. Illerhaus, S. Kubicka, S. Held, C.B. Westphalen, S. Kruger, S. Boeck, V. Heinemann
Journal: Annals of Oncology (2018)
P2.12-03 Phase I/II Trial Of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Authors: C. Kim, D. Subramaniam, S. Liu, G. Giaccone
Journal: Journal of Thoracic Oncology (2018)
P2.01-36 Real-World Treatment Patterns in Treatment-Naïve Advanced NSCLC Patients in North America: A Systematic Literature Review
Authors: A. Gara, N. Varol, S. Goring, T. Li, M. Oviedo Ovando, Y. Yuan, N. Hertel, B. Korytowsky
Journal: Journal of Thoracic Oncology (2018)
Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)
Authors: J. Wolf, T. Seto, J.-Y. Han, N. Reguart, E.B. Garon, H.J.M. Groen, D.S. Tan, T. Hida, M.J.A. de Jonge, S.V. Orlov, E.F. Smit, P.-J. Souquet, J.F. Vansteenkiste, M. Giovannini, S. Le Mouhaer, A. Robeva, M. Waldron-Lynch, R.S. Heist
Journal: Annals of Oncology (2018)
OA06.01 Case-Series Study in Ever- and Never-Smoking Females and Males with NSCLC: Exposures, Tumor Factors, Biology and Survival (SWOG S0424)
Authors: K. Albain, A. Darke, P. Mack, M. Redman, T. Cheng, J. Moon, W. Holland, A. Borczuk, C. Chay, P. Morris, E. Vallieres, R. Kratzke, J. Molina, J. Kolesar, Y. Chen, R. Macrae, S. Matsumoto, M. Reid, G. Zirpoli, W. Davis, R. Ondracek, W. Bshara, A. Omilian, D. Gandara, K. Kelly, R. Santella, C. Ambrosone
Journal: Journal of Thoracic Oncology (2018)
Type 3 cytokines IL-17A and IL-22 drive TGF-β–dependent liver fibrosis
Authors: Thomas Fabre, Manuel Flores Molina, Geneviève Soucy, Jean-Philippe Goulet, Bernard Willems, Jean-Pierre Villeneuve, Marc Bilodeau, Naglaa H. Shoukry
Journal: Science Immunology (2018)

Inflammatory immune cells can modulate activation of hepatic stellate cells (HSCs) and progression of liver fibrosis. Type 3 inflammation characterized by production of interleukin-17A (IL-17) and IL-22 by innate and adaptive immune cells is implicated in many inflammatory conditions of the gut and can be counteracted by regulatory T cells (Tregs), but its contribution to liver fibrosis is still poorly understood. Here, we evaluated the contribution of type 3 inflammation in liver fibrosis using clinical liver biopsies, in vitro stimulation of primary HSCs, and in vivo mouse models. We report dysregulated type 3 responses in fibrotic lesions with increased IL-17+CD4+/FOXP3hiCD4+ ratio and increased IL-17 and IL-22 production in advanced liver fibrosis. Neutrophils and mast cells were the main sources of IL-17 in situ in humans. In addition, we demonstrate a new profibrotic function of IL-22 through enhancement of transforming growth factor-β signaling in HSCs in a p38 mitogen-activated protein kinase-dependent manner. In vivo, IL-22RA1 knockout mice exhibited reduced fibrosis in response to thioacetamide and carbon tetrachloride. Blocking either IL-22 or IL-17 production using aryl hydrocarbon receptor or RAR-related orphan receptor gamma-t antagonists resulted in reduced fibrosis. Together, these data have identified a pathogenic role for type 3 immune response mediated by IL-22 in driving liver fibrosis during chronic liver injury.
MA13.05 The Canada Lymph Node Sonographic Score: National Validation of a Sonographic Score to Determine Mediastinal Lymph Node Malignancy
Authors: D. Hylton, J. Huang, S. Turner, D. French, C. Wen, J. Masters, B. Kidane, J. Spicer, J. Taylor, C. Finley, Y. Shargall, C. Fahim, F. Farrokhyar, K. Yasufuku, J. Agzarian, W. Hanna
Journal: Journal of Thoracic Oncology (2018)
First in human study with GSK3359609 [GSK609], inducible T cell co-stimulator (ICOS) receptor agonist in patients [Pts] with advanced, solid tumors: Preliminary results from INDUCE-1
Authors: A. Hansen, T.M. Bauer, V. Moreno, M. Maio, S. Groenland, J. Martin-Liberal, H. Gan, D. Rischin, M. Millward, A.J. Olszanski, D.C. Cho, E. Paul, M. Ballas, C. Ellis, H. Zhou, S. Yadavilli, J. Sadik Shaik, E.V. Schmidt, A. Hoos, E. Angevin
Journal: Annals of Oncology (2018)
Afatinib in combination with cisplatin and 5-fluorouracil (5-FU) as first line treatment in inoperable gastric and gastro-esophageal junction (GEJ) cancer: A phase II study by the Hellenic Cooperative Oncology Group
Authors: T. Makatsoris, E. Samantas, K. Manousou, V. Karavasilis, G. Aravantinos, D. Tryfonopoulos, A. Psyrri, D.G. Pectasides, E. Pazarli, C. Petraki, A. Tsipoura, I.G. Kaklamanos, G. Fountzilas, G. Pentheroudakis
Journal: Annals of Oncology (2018)
Usability testing of EirV3-a computer-based tool for patient reported outcome measures in cancer
Authors: H. Krogstad, S.M. Sundt-Hansen, M.J. Hjermstad, L.Å Hågensen, S. Kaasa, J.H. Loge, S.X. Raj, A. Steinsbekk, K. Sand
Journal: Annals of Oncology (2018)
P1.16-40 Evaluating the Tumor Heterogeneity in Lung Cancer by Constructing Tumor Heterogeneity Index (THI) from Magnetic Resonance Imaging
Authors: Q. Li, N. Gong, B. Qiu, H. He, J. Wang, Y. Ye, J. Guo, S. Lin, P. Cai, Q. Chen, H. Li, C. Xie, H. Liu
Journal: Journal of Thoracic Oncology (2018)
Abstract 18877: An Accurate Method for Automated Rhythm Classification During CPR
Authors: Heemun Kwok, Jason Coult, Jennifer Blackwood, Peter Kudenchuk, Lawrence Sherman, Thomas Rea
Journal: Circulation (2015)

Introduction: Accurate identification of the cardiac rhythm during CPR could facilitate appropriate defibrillation and guide medication treatments without interrupting chest compressions for rhythm analysis. Hypothesis: A rhythm classification method which “reads-through” CPR artifact would identify shockable rhythms with high sensitivity and non-shockable rhythms with high specificity during CPR. Methods: Two physicians annotated rhythms as shockable (VF or other shockable), non-shockable (asystole or organized) or indeterminate, throughout defibrillator recordings from a convenience sample of 185 treated OHCA cases. CPR was determined from impedance and/or accelerometer signals. Each ECG tracing was divided into consecutive 4-second frames, and only frames during CPR were included. The “read-through” method was derived from a development set (N=95 cases) and uses features generated by cross-correlation with a series of QRS-like wavelets and a hidden Markov model to integrate sequential data. In the validation set (N=90 cases), frame-by-frame classifications (shockable vs. non-shockable) were compared to the gold standard of physician assessment. Sensitivity and specificity were estimated using a multilevel model to account for clustering of frames within cases. Results: The validation set included a median 456 (IQR 179, 756) seconds of ECG data from each case. Overall, there were 13,851 4-second frames: 10% shockable, 88% non-shockable and 2% indeterminate. Mean sensitivity for VF was 0.97 (95% CI 0.84, 0.99), and specificities for an organized rhythm and asystole were 0.99 (95% CI 0.99, 1.0) and 0.99 (95% CI 0.97, 1.0), respectively. There was moderate variability in VF sensitivity across cases (IQR 0.77, 1.0). Conclusion: A “read-through” CPR method classified the shockable versus non-shockable rhythms with high overall sensitivity and specificity, though with some variability across individual patients.
Abiraterone acetate plus prednisone and LHRH therapy versus abiraterone acetate plus prednisone while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer: Results from the SPARE-trial (NCT02077634)
Authors: C. Ohlmann, Z. Roger, C. Rüssel, E. Hellmis, H. Suttmann, M. Janssen, A. Hübner, J. Dahm, J. Gleißner, M. Scheffler, S. Feyerabend, J. Telle, J. Klier
Journal: Annals of Oncology (2018)
Early prediction of revascularisation by angiomotin-targeting positron emission tomography
Authors: Anais Moyon, Philippe Garrigue, Laure Balasse, Samantha Fernandez, Pauline Brige, Marie Nollet, Guillaume Hache, Marcel Blot-Chabaud, Françoise Dignat-George, Benjamin Guillet
Journal: Theranostics (2018)

This study aimed to develop a PET imaging agent of angiomotin (AMOT) expression, a potential biomarker of functional tissue regeneration in post-ischaemic conditions. Methods: Hindlimb ischaemia was induced by ligature and resection of the right femoral artery in mice, and clinical score and limb perfusion were evaluated up to 30 days after surgery. AMOT expression was evaluated by histology and Western blot analysis. NODAGA-conjugates of AMOT ligand, sCD146, were designed, synthesised and radiolabelled with gallium-68. 68Ga-sCD146 microPET/CT imaging was performed from day 1 to day 30 after ischaemia. 68Ga-sCD146 specificity for AMOT was evaluated by autoradiography. Results: Immunohistochemistry showed a significant endothelial overexpression of AMOT from day 5 up to day 10 in the ischaemic hindlimb. 68Ga-sCD146 PET signal intensity correlated significantly with AMOT immunohistochemistry evaluation. 68Ga-sCD146 PET imaging showed a significant uptake in the ischaemic hindlimb from day 2 to day 15, peaking on day 5 (ipsi/contralateral ratio = 2.4 ± 1.3, P = 0.0005) and significantly decreased after pharmacological blocking (62.57 ± 11% decrease in PET signal P = 0.032). Finally, we observed a significant correlation between day 5 68Ga-sCD146 PET signal intensity and clinical recovery (day 28) or hindlimb perfusion recovery (day 30). Conclusions: This work reports for the first time an early and sustained increase in AMOT expression after hindlimb ischaemia in mice. We therefore developed an AMOT-targeting imaging agent, 68Ga-sCD146, and showed its specific uptake up to 21 days after ischaemic hindlimb using microPET imaging. Correlation of early post-ischaemic PET signal with both delayed perfusion recovery and clinical outcome allows us to postulate that 68Ga-sCD146 represents a promising radiotracer for tissue angiogenesis assessment.
Public Health England has not been captured by the alcohol industry
Authors: John Newton
Journal: BMJ (2018)

Public Health England (PHE) has a duty to protect and improve the health of the nation. The continuing health harms of alcohol require action,1 and PHE has been prominent in promoting a range of effective interventions, including minimum unit pricing.2

Partnering with the charity Drinkaware enables us to improve and inform the work of another body already …
Patterns of progression to immune checkpoint targeted monoclonal antibodies in phase I trials
Authors: A. Bernard-Tessier, C. Baldini, E. Castanon Alvarez, S. Ammari, P. Martin Romano, S. Champiat, A. Hollebecque, S. Postel-Vinay, A. Varga, R. Bahleda, A. Gazzah, J.-M. Michot, V. Ribrag, J.-P. Armand, A. Marabelle, J.-C. Soria, C. Massard
Journal: Annals of Oncology (2018)
Abstract 14509: Multicenter Randomized Controlled Trial Between Febuxostat and Allopurinol in Chronic Heart Failure Patients With Hyperuricemia
Authors: Satoshi Suzuki, Akiomi Yoshihisa, Akihiko Sato, Takeshi Shimizu, Takamasa Sato, Nobuo Sakamoto, Kazuhiko Nakazato, Tatsunori Tsuda, Akihiro Tsuda, Jun Goto, Toshiyuki Ishibashi, Ichiro Konno, Osamu Yamaguchi, Hirofumi Machii, Naoki Nozaki, Takeshi Niizeki, Takuya Miyamoto, Isao Kubota, Yasuchika Takeishi
Journal: Circulation (2017)

Background: Hyperuricemia is known as a marker of oxidative stress and associated with adverse prognosis in patients with chronic heart failure (CHF). Febuxostat, a novel non-purine selective xanth...
Trimodality therapy in the treatment of stage IIIA non-small cell lung cancer (NSCLC): Analysis of the National Cancer Database.
Authors: Madhusmita Behera, Conor Ernst Steuer, Felix Fernandez, Yuan Liu, Chao Fu, Theresa Wicklin Gillespie, Kristin Ann Higgins, Nabil F. Saba, Rathi Narayana Pillai, Seth Force, Suchita Pakkala, Dong Moon Shin, Taofeek Kunle Owonikoko, Chandra Prakash Belani, Walter J. Curran, Fadlo Raja Khuri, Suresh S. Ramalingam
Journal: Journal of Clinical Oncology (2015)

7514 Background: Significant controversy remains regarding the care of patients (pts) with clinical stage IIIA NSCLC. While multi-modality therapy is an acceptable strategy in selected pts, the optimal approach is not firmly established. We analyzed outcomes and predictors associated with trimodality therapy (TT) in the National Cancer Database (NCDB). Methods: The NCDB was queried from 2003-2011 for NSCLC pts diagnosed with stage IIIA-N2 disease and treated with chemotherapy and radiation (CRT). Three cohorts of pts were studied - CRT only/no surgery (NS), CRT + lobectomy (L) and CRT + pneumonectomy(P). The univariate and multivariable analyses (MV) were conducted using Cox proportional hazards model and log rank tests. All analyses were performed using SAS Version 9.3. Results: A total of 29,584 pts were included in this analysis: NS-91.7%, L-7%, and P-1.5%. Pt characteristics: median age 66 years (yrs); males 56%; whites 86%; academic centers 27%; metro locations 78%; government insured 63%; Charlson/Deyo comorbidity score 0 in 66%. Pts < 60 yrs were more likely to receive TT- L (47%), P (60%) vs. NS (29%); p< 0.001. Pts in academic centers were more likely to get TT than NS (42% vs. 25%). On MV analysis, L and P had significantly better survival vs. NS: HR 0.43 (0.38-0.48) and HR 0.57 (0.46-0.71) respectively; p < 0.001. The median survival of L, P and NS were 44.5 m vs. 25.6 m vs. 15.7 m (p < 0.001) and 5- year survival rates (SR) were 44% vs. 33% vs. 14% respectively. 30-day mortality was higher in P vs. L [7% vs. 2.6%; OR 0.26(0.16-0.45); p< 0.001]. Pts with < 2 lymph nodes (LN) had better survival than pts with > 2 LNs in L (50% vs. 37%; 60m vs. 38.8m) but worse in NS (13.8% vs.16.4%; 15.3m vs.18.5m). On MV analysis of LNs, L had better survival than NS: HR 0.4 (0.35-0.46) in < 2 LN pts and HR 0.56 (0.46-0.69) in ≥ 2 LN pts; p< 0.001. In pts with < 2 LN, L had better survival than P (60m vs. 25.5m; p< 0.0001). L and P had better SR than NS in all ages: 48% vs.37% vs. 19% in ≤ 60 yrs; 42% vs. 30% vs.14% in 61-70 yrs, 36% vs.19% vs. 10% in > 70 yrs. Conclusions: TT was utilized in less than 10% of pts with stage IIIA-N2 disease, suggesting high degree of pt selection. In this selected group, TT was associated with favorable outcomes relative to CRT alone.
MA10.06 Impact of Immune-Related Adverse Events on Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Nivolumab
Authors: B. Ricciuti, C. Genova, A. De Giglio, M. Brambilla, M. Bassanelli, M.G. Dal Bello, S. Baglivo, G. Metro, F. Grossi, R. Chiari
Journal: Journal of Thoracic Oncology (2018)
PI3K inhibition and modulation of immune and tumor microenvironment markers by copanlisib in patients with non-Hodgkin's lymphoma or advanced solid tumors
Authors: A.H. Awada, F. Morschhauser, J.-P. Machiels, G. Salles, S. Rottey, S. Rule, D. Cunningham, F. Peyrade, C. Fruchart, H.-T. Arkenau, I. Genvresse, K. Koechert, G. Cisternas, C. Granvil, C. Pena, L. Liu
Journal: Annals of Oncology (2018)
Clinical and Neurofunctional Substrates of Cognitive Behavioral Therapy on Secondary Social Anxiety Disorder in Primary Panic Disorder: A Longitudinal fMRI Study
Authors: Fabian Seeger, Yunbo Yang, Benjamin Straube, Tilo Kircher, Michael Höfler, Hans-Ulrich Wittchen, Andreas Ströhle, André Wittmann, Alexander L. Gerlach, Bettina Pfleiderer, Volker Arolt, Alfons Hamm, Thomas Lang, Georg W. Alpers, Thomas Fydrich, Ulrike Lueken
Journal: Psychotherapy and Psychosomatics (2018)
Preliminary results of PROCLAIM-CX-072: The first-in-human, dose-finding trial of PD-L1 probody therapeutic CX-072 as monotherapy in patients (pts) with advanced solid tumors
Authors: V. Boni, J. Garcia-Corbacho, P.A. Ott, D.C. Cho, K.A. Autio, N. Uboha, A.I. Spira, R. Humphrey, M. Will, A. Naing, F. Thistlethwaite, E.G.E. de Vries, H.-T. Arkenau
Journal: Annals of Oncology (2018)
Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukine-2 to standard ipilimumab treatment in metastatic melanoma
Authors: M.W. Rohaan, T.H. Borch, J.H. van den Berg, M.H. Geukes Foppen, M. Donia, Ö Met, B. Nuijen, M. van Zon, E.A.M. Bakker, R. de Boer, L.M. Pronk, S. Wilgenhof, C.U. Blank, J.V. van Thienen, A.C.J. van Akkooi, I.-M. Svane, J.B.A.G. Haanen
Journal: Annals of Oncology (2018)
<scp>EASI</scp> p‐<scp>EASI</scp>: Predicting disease severity in atopic dermatitis patients treated with cyclosporin A
Authors: Judith L. Thijs, Julia Drylewicz, Carla A. F. M. Bruijnzeel‐Koomen, Barbara Giovannone, Edward F. Knol, Marjolein S. de Bruin‐Weller, Stefan Nierkens, DirkJan Hijnen
Journal: Allergy (2018)
P1.01-76 A Phase II Trial of Albumin-Bound Paclitaxel and Gemcitabine in Patients with Newly Diagnosed Stage IV Squamous Cell Lung Cancers
Authors: P. Paik, R. Kim, L. Ahn, A. Plodkowski, K. Ng, D. Mcfarland, A. Iqbal, J. Eng, C. Rudin
Journal: Journal of Thoracic Oncology (2018)
P2.15-25 NIVEX TRIAL (GECP 1605): Nivolumab in the Real World: Spanish Expanded Access Program Experience in Pretreated Advanced NSCLC Patients
Authors: D. Rodríguez-Abreu, J. Campillo, F. Grau, E. Carcereny, R. Bernabé, Y. Garcia, A. Artal Cortes, M. Gonzalez Cao, O. Juan, F. Garicano, I. Gil-Bazo, R. Blanco, M. Guillot, M. Provencio, M. Majem
Journal: Journal of Thoracic Oncology (2018)
ISO-CC-005; A phase I/II study of arfolitixorin (MTHF) in combination with 5-FU, irinotecan, and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer
Authors: G.U. Carlsson, T.K. Guren, J. Haux, P. Pfeiffer, H. Taflin, D. Mavroudis, V. Georgoulias, C. Papadimitriou, N. Kentepozidis, D. Boumpas, L. Skintemo, K.M.E. Ganlöv, B. Gustavsson
Journal: Annals of Oncology (2018)
A multicenter phase II trial of perioperative capecitabine plus oxaliplatin for clinical stage III gastric cancer (OGSG1601)
Authors: R. Kawabata, T. Terazawa, J. Matsuyama, S. Endo, O. Shiraishi, S. Fujita, Y. Akamaru, H. Taniguchi, M. Tatsumi, M. Gotoh, S.-W. Lee, Y. Kurokawa, T. Shimokawa, D. Sakai, T. Kato, K. Fujitani, T. Satoh
Journal: Annals of Oncology (2018)
Validation of a 90-gene assay for tissue origin diagnosis of brain metastases
Authors: Y. Zheng, Y. Ding, C. Xiao, W. Zhong, X. Teng, Q. Gao, Q. Wang, Y. Sun, C. Chen, L. Chen, J. Zhu, Q. Xu, N. Xu
Journal: Annals of Oncology (2018)
Incidence of inflammatory polyarthritis in polymyalgia rheumatica: a population-based cohort study
Authors: Max Yates, Jalpa Kotecha, Richard A Watts, Robert Luben, Kay-Tee Khaw, Alexander J MacGregor
Journal: Annals of the Rheumatic Diseases (2018)

The relationship between polymyalgia rheumatica (PMR) and inflammatory polyarthritis (IP) remains a source of debate in rheumatology: although both conditions have been classified separately as distinct entities, they share many clinical features.1–4 It remains unclear whether synovitis in IP is part of a spectrum of PMR, or if the symptoms of PMR are early manifestations of a distinct diagnosis of IP. Alternatively, the arthritis that develops in PMR might represent a phenotypic transformation in susceptible individuals.

We examined the risk of IP following the diagnosis of PMR in the data from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Norfolk study, a prospective population-based cohort.5 Incident cases of PMR were identified retrospectively among 24 068 volunteers enrolled after 2002 by (1) free-text questionnaire responses at baseline, 18 months, and at 3, 10 and 13 years; (2) linkage to hospital electronic discharge summaries containing International Classification of Diseases codes; and (3) linkage to keyword searches ( polymyalgia or rheumatica ) of outpatient clinic letters. To be identified as PMR, participants were required to …
Brain Tissue–Volume Changes in Cosmonauts
Authors: Angelique Van Ombergen, Steven Jillings, Ben Jeurissen, Elena Tomilovskaya, R Maxine Rühl, Alena Rumshiskaya, Inna Nosikova, Liudmila Litvinova, Jitka Annen, Ekaterina V Pechenkova, Inessa B Kozlovskaya, Stefan Sunaert, Paul M Parizel, Valentin Sinitsyn, Steven Laureys, Jan Sijbers, Peter Zu Eulenburg, Floris L Wuyts
Journal: New England Journal of Medicine (2018)

Changes in Brain Volume in Cosmonauts Ten cosmonauts, who spent an average of 189 days in space, had changes in brain volumes — mainly decreased cortical volume and increased CSF subarachnoid and v...
Pharmacokinetic (PK) analysis of concurrent administration of enzalutamide (enza) and crizotinib (crizo) in patients with metastatic castration resistant prostate cancer (CRPC)
Authors: A. tripathi, J.G. Supko, K.P. Gray, Z. Melnick, M.-E. Taplin, A.D. Choudhury, M. Pomerantz, J. Bellmunt, C. Yu, Z. Sun, S. Srinivas, P.W. Kantoff, C. Sweeney, L.C. Harshman
Journal: Annals of Oncology (2018)
A phase II study of pemetrexed and erlotinib for metastatic colorectal cancer refractory to standard chemotherapy
Authors: S.-H. Beom, K.-W. Lee, S.-H. Cho, Y.S. Park, T.W. Kim, K.H. Lee, M. Jung, S.J. Shin, J.B. Ahn
Journal: Annals of Oncology (2018)
Longitudinal plasma monitoring of subjects treated with EGFR-TKIs allows better understanding of evolution of acquired resistance and can inform optimal treatment strategies
Authors: J. Palma, P. Vitazka, N. Tikoo, A. Balasubramanyam, L. Xi, S. Yaung, E. Kwok, A. Lovejoy, D. Klass, M. Heibeck, K. Probst, A. Rehfeldt, E. Meldgaard, A. Madsen, M. Clement, B. Sorensen, P. Meldgaard
Journal: Annals of Oncology (2018)
Abstract 20755: Keeping Calm While Solving the Puzzle: An Uncommon Case of Hypertensive Emergency
Authors: Michael F Bode, Weeranun D Bode
Journal: Circulation (2016)

A 50-year-old man with diabetes was transferred for non-ST segment elevation myocardial infarction. He presented with a 4-day history of chest pain, diaphoresis, nausea, vomiting, headache, and syn...